2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-116400
    BN 50341 107550-66-3 98%
    BN 50341 is an orally active anticalcic agent and a benzazepine derivative. BN 50341 decreases the in vivo electrically induced thrombus formation in rat or guinea-pig artery and can be utilized in cardiovascular research.
    BN 50341
  • HY-116431
    I-BOP 128719-90-4 98%
    I-BOP is an agonist for thromboxane A2 receptor (TP) with a KD of 0.61 nM. I-BOP promotes proliferation through activation of PI3K pathway in vascular smooth muscle. I-BOP dose-dependently biphasicly affects the excitatory postsynaptic potential (e.p.s.p.) in hippocampal neurons.
    I-BOP
  • HY-116457
    Propanidid 1421-14-3 98.19%
    Propanidid (Sombrevin; Fabantol) is a γ-aminobutyric acid type A (GABAA) receptor agonist and a short-acting non-barbiturate general agent that can suppress or relieve pain. Propanidid can decrease the arterial pressure.
    Propanidid
  • HY-116481
    Selenotifen 135472-91-2 98%
    Selenotifen (BN 52256) is an antiallergic agent. Selenotifen is a highly potent antagonist to PAF receptors. Selenotifen exhibits a statistically significant antiarrhythmic effect.
    Selenotifen
  • HY-116509
    Linoleylanilide 19878-10-5 98%
    Linoleylanilide (Linoleic acid anilide) is a Linoleic acid (HY-N0729) derivative. Linoleylanilide slightly inhibits the PMA (HY-18739)-induced expression of CD11b. Linoleylanilide inhibits serum LDH, GOT and GPT activities. Linoleylanilide decreases red cell counts and hemoglobin content.
    Linoleylanilide
  • HY-116540
    L 858051 110452-75-0 98%
    L 858051 (7DMB-Forskolin free base), an analog of Forskolin (HY-15371), is an adenylyl cyclase stimulator. L 858051 directly activates adenylyl cyclase to increase intracellular, cellular, and ciliary cAMP levels. L 858051 activates recombinant cyclic nucleotide-gated (E583M CNGA2) channels to induce a non-selective, Mg2+-sensitive current in adult rat ventricular myocytes. L 858051 maximally stimulates L-type Ca2+ current in adult rat ventricular myocytes. L 858051 increases total PDE3 and PDE4 activities in adult rat ventricular myocytes, with effects insensitive to PKA inhibition. L 858051 serves as a tool to elevate intracellular cAMP for studying subsarcolemmal cAMP dynamics and compartmentation in adult rat ventricular myocytes.
    L 858051
  • HY-116556
    Rilmakalim 132014-21-2 98%
    Rilmakalim (HOE 234) is a potassium channel opener (PCO) that activates ATP-sensitive K+ channels in the heart or other tissues.
    Rilmakalim
  • HY-116569
    VU0455691 1392443-41-2 98%
    VU0455691 is a potent, selective orthosteric M1 mAChR antagonist (pIC50=6.64; IC50=0.23 µM for hM1).
    VU0455691
  • HY-116613
    FR-181877 172936-99-1 98%
    FR-181877 (compound 4) is a non-prostaglandin PGI2 agonist. FR-181877 inhibits ADP (HY-W010918)-induced human platelet aggregation with an IC50 value of 0.081 μM.
    FR-181877
  • HY-116678
    Cloricromen 68206-94-0 98%
    Cloricromen (Cloricromene) is an orally active platelet inhibitor. Cloricromen inhibits thromboxane B2 release, β-thromboglobulin, and thrombus formation. Cloricromen inhibits LPS (HY-D1056)-induced NF-κB activation, oxidative activity, and TNF-α expression. Cloricromen exhibits protective activity in animal models of shock and peripheral ischaemia. Cloricromen can be used for the research of myocardial ischaemia/reperfusion injury, and ischaemic cerebrovascular disease.
    Cloricromen
  • HY-116718
    UTA1inh-D1 892745-28-7 98%
    UTA1inh-D1 is a selective UT-A1 and UT-B urea transporter inhibitor with IC50 values of 3.8 μM and 15 μM, respectively. UTA1inh-D1 is promising for research of refractory edema, such as congestive heart failure and cirrhosis.
    UTA1inh-D1
  • HY-116721
    AG-28262 638216-89-4 98%
    AG-28262 is a VEGFR inhibitor. AG-28262 has anti-angiogenesis activity.
    AG-28262
  • HY-116757
    (±)-α-CMBHC 7083-09-2 98%
    (±)-α-CMBHC is a metabolite of α-Tocopherol.
    (±)-α-CMBHC
  • HY-116759
    VU0405601 712325-30-9 99.93%
    VU0405601 is a potent KV11.1 channel activator. VU0405601 protects cardiac tissue from dofetilide (HY-B0232)-induced ventricular tachycardia.
    VU0405601
  • HY-116960
    FR 76830 113243-75-7 98%
    FR 76830 is a bradycardic agent with cardiomyocyte protective effects. FR 76830 attenuates the decrease in myocardial pH during the early stage of ischemia. FR 76830 improves ATP levels during the late stage of ischemia. FR 76830 reduces heart rate in a dose-dependent manner without decreasing the rate-pressure product of the myocardium. FR 76830 exerts cardioprotective effects during ischemia and reperfusion. FR 76830 can be used for the research of myocardial ischemia-reperfusion injury.
    FR 76830
  • HY-117135
    HNS-32 186086-10-2 98%
    HNS-32 is a compound with antiarrhythmic and vasodilatory effects in canine hearts, showing superior protective effects against ischemic and reperfusion arrhythmias compared to an equivalent dose of Mexiletine hydrochloride (HY-A0093). Furthermore, HNS-32 exhibits significant negative chronotropic effects on mammalian ventricular myocardium, indicating its potential application value in the study of acute coronary syndrome.
    HNS-32
  • HY-117174
    L-735821 170228-29-2 98%
    L-735821 is a Potassium channel blocker and an antagonist of IKs. L-735821 inhibits the KCNQ1 channel activity with an EC50 of 0.08 μM. L-735821 can increase IKs and IKr current-voltage relations in rabbit ventricular myocytes. L-735821 fully abolishes IKs in isolated human ventricular myocytes at 100 nmol/L. L-735821 can easily enter single myocytes.
    L-735821
  • HY-117177
    XV459 170902-52-0 98%
    XV459 is an orally active platelet GPIIb/IIIa receptor antagonist. XV459 blocks all agonist induced platelet aggregation by binding to platelet GPIIb/IIIa receptors. XV459 can significantly prolong occlusion time, reduce thrombus weight, and maintain blood flow. XV459 can be used for anti thrombotic research.
    XV459
  • HY-117181
    UK-1745 170684-14-7 98%
    UK-1745 is a cardiotonic agent with vasodilating and antiarrhythmic properties. It increases intracellular levels of cyclic adenosine monophosphate (cAMP) in cardiomyocytes by inhibiting phosphodiesterase III, thereby enhancing myocardial contractility. Additionally, UK-1745 exhibits β-adrenergic receptor blocking activity, which helps reduce the oxygen consumption of the heart and prevent calcium overload. These characteristics make UK-1745 a promising candidate for research in congestive heart failure.
    UK-1745
  • HY-117239
    SB-206606 116049-78-6 98%
    SB-206606, a stereoisomer of BRL 37344, is a potentially specific, beta 3-adrenergic receptor (β3-AR) ligand. The affinity of [3H]SB 206606 is 76 times higher for the β3-AR than for the beta 1/beta 2-adrenergic receptors.
    SB-206606
Cat. No. Product Name / Synonyms Application Reactivity